Everolimus in patients with autosomal dominant polycystic kidney disease.

BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy to curtail cyst growth and prevent renal failure is not available. Experimental and observational studies suggest that the mammalian target of rapamycin (mTOR) pathway plays a critical role in cyst growth. METHODS In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD to receive either placebo or the mTOR inhibitor everolimus. The primary outcome was the change in total kidney volume, as measured on magnetic resonance imaging, at 12 and 24 months. RESULTS Total kidney volume increased between baseline and 1 year by 102 ml in the everolimus group, versus 157 ml in the placebo group (P=0.02) and between baseline and 2 years by 230 ml and 301 ml, respectively (P=0.06). Cyst volume increased by 76 ml in the everolimus group and 98 ml in the placebo group after 1 year (P=0.27) and by 181 ml and 215 ml, respectively, after 2 years (P=0.28). Parenchymal volume increased by 26 ml in the everolimus group and 62 ml in the placebo group after 1 year (P=0.003) and by 56 ml and 93 ml, respectively, after 2 years (P=0.11). The mean decrement in the estimated glomerular filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 of body-surface area in the everolimus group versus 7.7 ml per minute in the placebo group (P=0.15). Drug-specific adverse events were more common in the everolimus group; the rate of infection was similar in the two groups. CONCLUSIONS Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)

[1]  J. Felmlee,et al.  Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. , 2003, Kidney international.

[2]  L. Antiga,et al.  Sirolimus therapy to halt the progression of ADPKD. , 2010, Journal of the American Society of Nephrology : JASN.

[3]  F. Cosio,et al.  Sirolimus reduces polycystic liver volume in ADPKD patients. , 2008, Journal of the American Society of Nephrology : JASN.

[4]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[5]  Ming Wu,et al.  Everolimus Retards Cyst Growth and Preserves Kidney Function in a Rodent Model for Polycystic Kidney Disease , 2007, Kidney and Blood Pressure Research.

[6]  A. Novick,et al.  The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Paul A Thompson,et al.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. , 2003, Kidney international.

[8]  Chengqing Wu,et al.  Sequential testing for efficacy in clinical trials with non‐transient effects , 2005, Statistics in medicine.

[9]  W. Lieberthal,et al.  The role of the mammalian target of rapamycin (mTOR) in renal disease. , 2009, Journal of the American Society of Nephrology : JASN.

[10]  P. Wahl,et al.  Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Y. Tao,et al.  Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  G. Brosnahan,et al.  Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.

[13]  J. García Rodríguez,et al.  [Polycystic Kidney Disease]. , 2005, Actas urologicas espanolas.

[14]  E. Henske,et al.  The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway , 2008, Human molecular genetics.

[15]  R. Sandford,et al.  Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. , 2009, Human molecular genetics.

[16]  J. Reiter,et al.  The Primary Cilium as the Cell's Antenna: Signaling at a Sensory Organelle , 2006, Science.

[17]  G. Filler,et al.  Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.